Leerink analyst Paul Matteis raised his price target for shares of GW Pharmaceuticals to $120 after the American Academy of Neurology disclosed updated Epidiolex data from 137 patients. Matteis calls the data better than expectations saying they showed a "much greater" magnitude of overall seizure reduction than in the October update and a "consistent, robust effect" in larger samples of Dravet and Lennox Gastaut patients. He now assumes higher Epidiolex peak market penetrations and more use in the broader refractory pediatric epilepsy population. The analyst reiterates an Outperform rating on GW Pharmaceuticals. The stock closed yesterday at $96.18 and is trading up $7.87 to $104.05 in premarket trading.